TSS
VOR icon

Two Sigma Securities’s Vor Biopharma VOR Stock Holding History

Two Sigma Securities’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,720
Closed -$153K – 2039
2025
Q2 		$153K Buy
+4,720
New +$41.7K 0.02% 988
2025
Q1 		– Sell
-503
Closed -$11.2K – 2267
2024
Q4 		$11.2K Buy
+503
New +$8.34K ﹤0.01% 1424

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Ariose Capital Management Central, Hong Kong, Hong Kong $149M AUM 287.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Securities's VOR Position: Q3 2025 in Review

Two Sigma Securities sold out of Vor Biopharma (VOR) in Q3 2025, closing a stake of 4,720 shares — an estimated $153K sold.

Two Sigma Securities first reported a position in VOR in Q4 2024 and held it in 2 quarters. The position peaked at $153K in Q2 2025. 37 funds tracked by Wall St. Rank hold VOR as of Q3 2025.

  • Two Sigma Securities reported no remaining Vor Biopharma position as of Q3 2025 after selling out during the quarter.
  • Two Sigma Securities sold 4,720 Vor Biopharma shares in Q3 2025, an estimated $153K.
  • Two Sigma Securities first reported a position in Vor Biopharma in Q4 2024 and held it in 2 quarters.
  • Two Sigma Securities's Vor Biopharma position peaked at $153K in Q2 2025.
  • 37 funds tracked by Wall St. Rank held Vor Biopharma as of Q3 2025.

Based on Two Sigma Securities's 13F filing for Q3 2025, filed 14 Nov 2025.